Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer

Apostolia Maria Tsimberidou, Wallace Akerley, Matthias Schabel, David S. Hong, Cynthia Uehara, Anil Chhabra, Terri Warren, Gary G. Mather, Brent A. Evans, Deane P. Woodland, Edward A. Swabb, Razelle Kurzrock

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

MPC-6827 (Azixa) is a small-molecule microtubule-destabilizing agent that binds to the same(or nearby) sites on β-tubulin as colchicine. This phase I study was designed to determine the dose-limiting toxicities (DLT), maximumtolerated dose(MTD), and pharmacokinetics (PK) ofMPC-6827 in patients with solid tumors. Patients with advanced/metastatic cancer were treated with once-weekly, 1- to 2-hour intravenous administration of MPC-6827 for 3 consecutive weeks every 28 days (1 cycle). Dose escalation began with 0.3, 0.6, 1, and 1.5mg/m2, with subsequent increments of 0.6 mg/m2 until the MTD was determined. A 3 + 3 design was used. Pharmacokinetics ofMPC-6827 and itsmetaboliteMPI-0440627 were evaluated. Forty-eight patients received therapy; 79 cycleswere completed(median, 1; range, 1-10). Themost common adverse eventswere nausea, fatigue, flushing, and hyperglycemia. The DLT was nonfatal grade 3 myocardial infarction at 3.9 mg/m2 (1/6 patients) and at 4.5mg/m2 (1/7 patients).TheMTDwas determined to be 3.3mg/m2 (0/13 patients had aDLT). Five (10.4%) of the 48 patients achieved stable disease (Response Evaluation Criteria in Solid Tumors) for 4 months or greater. MPC-6827 has a high volume of distribution and clearance. Half-life ranged from 3.8 to 7.5 hours. In conclusion, MPC-6827 administered intravenously over 2 hours at a dose of 3.3mg/m2 onceweekly for 3weeks every 28days was safe in patients with heavily pretreatedcancer. Clinical trials withMPC-6827 and chemotherapy are ongoing.

Original languageEnglish (US)
Pages (from-to)3410-3419
Number of pages10
JournalMolecular Cancer Therapeutics
Volume9
Issue number12
DOIs
StatePublished - Dec 2010
Externally publishedYes

Fingerprint

Clinical Trials, Phase I
Proxy
Microtubules
Neoplasms
Pharmacokinetics
verubulin
Colchicine
Tubulin
Hyperglycemia
Intravenous Administration
Nausea
Fatigue
Half-Life
Myocardial Infarction
Clinical Trials
Drug Therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer. / Tsimberidou, Apostolia Maria; Akerley, Wallace; Schabel, Matthias; Hong, David S.; Uehara, Cynthia; Chhabra, Anil; Warren, Terri; Mather, Gary G.; Evans, Brent A.; Woodland, Deane P.; Swabb, Edward A.; Kurzrock, Razelle.

In: Molecular Cancer Therapeutics, Vol. 9, No. 12, 12.2010, p. 3410-3419.

Research output: Contribution to journalArticle

Tsimberidou, AM, Akerley, W, Schabel, M, Hong, DS, Uehara, C, Chhabra, A, Warren, T, Mather, GG, Evans, BA, Woodland, DP, Swabb, EA & Kurzrock, R 2010, 'Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer', Molecular Cancer Therapeutics, vol. 9, no. 12, pp. 3410-3419. https://doi.org/10.1158/1535-7163.MCT-10-0516
Tsimberidou, Apostolia Maria ; Akerley, Wallace ; Schabel, Matthias ; Hong, David S. ; Uehara, Cynthia ; Chhabra, Anil ; Warren, Terri ; Mather, Gary G. ; Evans, Brent A. ; Woodland, Deane P. ; Swabb, Edward A. ; Kurzrock, Razelle. / Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer. In: Molecular Cancer Therapeutics. 2010 ; Vol. 9, No. 12. pp. 3410-3419.
@article{fa0f2426770043be9a529a02aba13354,
title = "Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer",
abstract = "MPC-6827 (Azixa) is a small-molecule microtubule-destabilizing agent that binds to the same(or nearby) sites on β-tubulin as colchicine. This phase I study was designed to determine the dose-limiting toxicities (DLT), maximumtolerated dose(MTD), and pharmacokinetics (PK) ofMPC-6827 in patients with solid tumors. Patients with advanced/metastatic cancer were treated with once-weekly, 1- to 2-hour intravenous administration of MPC-6827 for 3 consecutive weeks every 28 days (1 cycle). Dose escalation began with 0.3, 0.6, 1, and 1.5mg/m2, with subsequent increments of 0.6 mg/m2 until the MTD was determined. A 3 + 3 design was used. Pharmacokinetics ofMPC-6827 and itsmetaboliteMPI-0440627 were evaluated. Forty-eight patients received therapy; 79 cycleswere completed(median, 1; range, 1-10). Themost common adverse eventswere nausea, fatigue, flushing, and hyperglycemia. The DLT was nonfatal grade 3 myocardial infarction at 3.9 mg/m2 (1/6 patients) and at 4.5mg/m2 (1/7 patients).TheMTDwas determined to be 3.3mg/m2 (0/13 patients had aDLT). Five (10.4{\%}) of the 48 patients achieved stable disease (Response Evaluation Criteria in Solid Tumors) for 4 months or greater. MPC-6827 has a high volume of distribution and clearance. Half-life ranged from 3.8 to 7.5 hours. In conclusion, MPC-6827 administered intravenously over 2 hours at a dose of 3.3mg/m2 onceweekly for 3weeks every 28days was safe in patients with heavily pretreatedcancer. Clinical trials withMPC-6827 and chemotherapy are ongoing.",
author = "Tsimberidou, {Apostolia Maria} and Wallace Akerley and Matthias Schabel and Hong, {David S.} and Cynthia Uehara and Anil Chhabra and Terri Warren and Mather, {Gary G.} and Evans, {Brent A.} and Woodland, {Deane P.} and Swabb, {Edward A.} and Razelle Kurzrock",
year = "2010",
month = "12",
doi = "10.1158/1535-7163.MCT-10-0516",
language = "English (US)",
volume = "9",
pages = "3410--3419",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer

AU - Tsimberidou, Apostolia Maria

AU - Akerley, Wallace

AU - Schabel, Matthias

AU - Hong, David S.

AU - Uehara, Cynthia

AU - Chhabra, Anil

AU - Warren, Terri

AU - Mather, Gary G.

AU - Evans, Brent A.

AU - Woodland, Deane P.

AU - Swabb, Edward A.

AU - Kurzrock, Razelle

PY - 2010/12

Y1 - 2010/12

N2 - MPC-6827 (Azixa) is a small-molecule microtubule-destabilizing agent that binds to the same(or nearby) sites on β-tubulin as colchicine. This phase I study was designed to determine the dose-limiting toxicities (DLT), maximumtolerated dose(MTD), and pharmacokinetics (PK) ofMPC-6827 in patients with solid tumors. Patients with advanced/metastatic cancer were treated with once-weekly, 1- to 2-hour intravenous administration of MPC-6827 for 3 consecutive weeks every 28 days (1 cycle). Dose escalation began with 0.3, 0.6, 1, and 1.5mg/m2, with subsequent increments of 0.6 mg/m2 until the MTD was determined. A 3 + 3 design was used. Pharmacokinetics ofMPC-6827 and itsmetaboliteMPI-0440627 were evaluated. Forty-eight patients received therapy; 79 cycleswere completed(median, 1; range, 1-10). Themost common adverse eventswere nausea, fatigue, flushing, and hyperglycemia. The DLT was nonfatal grade 3 myocardial infarction at 3.9 mg/m2 (1/6 patients) and at 4.5mg/m2 (1/7 patients).TheMTDwas determined to be 3.3mg/m2 (0/13 patients had aDLT). Five (10.4%) of the 48 patients achieved stable disease (Response Evaluation Criteria in Solid Tumors) for 4 months or greater. MPC-6827 has a high volume of distribution and clearance. Half-life ranged from 3.8 to 7.5 hours. In conclusion, MPC-6827 administered intravenously over 2 hours at a dose of 3.3mg/m2 onceweekly for 3weeks every 28days was safe in patients with heavily pretreatedcancer. Clinical trials withMPC-6827 and chemotherapy are ongoing.

AB - MPC-6827 (Azixa) is a small-molecule microtubule-destabilizing agent that binds to the same(or nearby) sites on β-tubulin as colchicine. This phase I study was designed to determine the dose-limiting toxicities (DLT), maximumtolerated dose(MTD), and pharmacokinetics (PK) ofMPC-6827 in patients with solid tumors. Patients with advanced/metastatic cancer were treated with once-weekly, 1- to 2-hour intravenous administration of MPC-6827 for 3 consecutive weeks every 28 days (1 cycle). Dose escalation began with 0.3, 0.6, 1, and 1.5mg/m2, with subsequent increments of 0.6 mg/m2 until the MTD was determined. A 3 + 3 design was used. Pharmacokinetics ofMPC-6827 and itsmetaboliteMPI-0440627 were evaluated. Forty-eight patients received therapy; 79 cycleswere completed(median, 1; range, 1-10). Themost common adverse eventswere nausea, fatigue, flushing, and hyperglycemia. The DLT was nonfatal grade 3 myocardial infarction at 3.9 mg/m2 (1/6 patients) and at 4.5mg/m2 (1/7 patients).TheMTDwas determined to be 3.3mg/m2 (0/13 patients had aDLT). Five (10.4%) of the 48 patients achieved stable disease (Response Evaluation Criteria in Solid Tumors) for 4 months or greater. MPC-6827 has a high volume of distribution and clearance. Half-life ranged from 3.8 to 7.5 hours. In conclusion, MPC-6827 administered intravenously over 2 hours at a dose of 3.3mg/m2 onceweekly for 3weeks every 28days was safe in patients with heavily pretreatedcancer. Clinical trials withMPC-6827 and chemotherapy are ongoing.

UR - http://www.scopus.com/inward/record.url?scp=78650450212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650450212&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-10-0516

DO - 10.1158/1535-7163.MCT-10-0516

M3 - Article

VL - 9

SP - 3410

EP - 3419

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 12

ER -